These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25091501)

  • 1. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
    Balar AV; Milowsky MI
    Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development.
    Balar AV; Milowsky MI
    Urol Clin North Am; 2015 May; 42(2):217-24, viii-ix. PubMed ID: 25882563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer.
    Takata R; Obara W; Fujioka T
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S41-5. PubMed ID: 20094952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced urothelial cancer.
    Yagoda A
    Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
    [No Abstract]   [Full Text] [Related]  

  • 5. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic chemotherapy for urothelial cancer.
    Sonpavde G; Hutson TE; Berry WR
    Clin Genitourin Cancer; 2006 Jun; 5(1):34-42. PubMed ID: 16859577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
    Walther PJ
    Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving role of chemotherapy in advanced urothelial cancer.
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients.
    Heidenreich A
    Eur Urol; 2008 Jul; 54(1):21-3. PubMed ID: 18262722
    [No Abstract]   [Full Text] [Related]  

  • 13. [Neoadjuvant chemotherapy for invasive bladder cancer].
    Kageyama Y; Kihara K
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1838-44. PubMed ID: 11729476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.
    Sternberg CN; Parmar MK
    J Clin Oncol; 2001 Sep; 19(18 Suppl):21S-26S. PubMed ID: 11560967
    [No Abstract]   [Full Text] [Related]  

  • 16. [Place of chemotherapy in the treatment of invasive bladder tumors].
    Pariente JL; Theodore C; Davin JL; Rischmann P; Chopin D
    Prog Urol; 1999 Apr; 9(2):219-24. PubMed ID: 10370944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of paclitaxel in the therapy of bladder cancer.
    Roth BJ
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):33-40. PubMed ID: 7481859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.